-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

--Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating

--Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating

MT Newswires · 01/06/2023 05:26